GlassScriptPhysician profile
Shahzad Manawar
NPI 1710915939
$119,597.39
in general payments reported to CMS, 2019-2025
43 companies · $30K in 2025
The $30K reported for 2025 was more than what 96% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,501 · 2020: $8,151 · 2021: $33K · 2022: $25K · 2023: $13K · 2024: $7,940 · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Honoraria: $9,600 · Food and Beverage: $6,721 · Travel and Lodging: $1,017 · Education: $894.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,453.60 |
| Honoraria | $9,600.00 |
| Food and Beverage | $6,720.82 |
| Travel and Lodging | $1,016.76 |
| Education | $894.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $95,017.53 | 2019-2025 | Breztri, Airsupra, Fasenra |
| Verona Pharma, INC. | $11,484.20 | 2025 | Ohtuvayre |
| Glaxosmithkline, LLC. | $3,229.17 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,962.53 | 2019-2025 | Ofev, Jascayd |
| Genzyme Corporation | $1,404.92 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $964.15 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $775.29 | 2019-2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $572.01 | 2019-2024 | Yupelri |
| Insmed, INC. | $476.36 | 2019-2025 | Brinsupri, Arikayce |
| Philips North America LLC | $297.12 | 2019-2025 | Vest Therapy Und, (8874) Incourage |
| Actelion Pharmaceuticals US, INC. | $258.58 | 2019-2024 | Opsumit, Uptravi |
| Teva Pharmaceuticals USA, INC. | $237.73 | 2019-2021 | |
| Pfizer INC. | $235.45 | 2019-2022 | |
| Electromed, INC. | $183.38 | 2021-2025 | Smartvest |
| Pulmonx Corporation | $183.08 | 2020-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shahzad Manawar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.